kentucky glp-1 pancreatitis class action Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Updates in Medicine | GLP-1s

GLP-1R/GIPR/GCGR signaling in neuroprotection

This phenomenon connects to how the medication alters metabolic rate and body composition during weight loss

Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the companys approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists, including Ozempic.

Korean pharmaceutical and biotech companies are heading to the American Diabetes Association (ADA) 2026 Scientific Sessions with obesity and metabolic disease pipelines that reflect the industry's shift beyond simple weight loss toward muscle preservation, management of metabolic comorbidities and m

Learn about expected results, dosage impact, and expert tips to maximize your weight loss journey.